Summary

Avience Biomedicals Limited is launching its SME IPO worth ₹30.24 crore. The company operates in the biotechnology, genomics, and IVD diagnostics industry and offers a wide range of molecular diagnostic products, rapid test kits, analyzers, and medical equipment. With healthy profitability, strong return ratios, and expanding operations, the IPO has attracted investor attention. As of June 15, 2026, the Avience Biomedicalas IPO GMP stood at ₹40.

About Avience Biomedicals Limited

Avience Biomedicals Limited is an ISO-certified company engaged in manufacturing, trading, supplying, and exporting diagnostic products and medical devices. The company primarily serves hospitals, pathology laboratories, microbiology laboratories, and research institutions in India and overseas.

Its product portfolio includes:

• Rapid Test Kits

• Molecular Diagnostic Products

• Biochemistry Reagents and Analyzers

• Hematology Analyzers

• Serology Products

• Medical Equipment

Apart from manufacturing, the company also distributes and trades medical devices to cater to growing healthcare demand.

Avience Biomedicalas IPO Details

Avience Biomedicalas IPO GMP Today

The Avience Biomedicalas IPO GMP (Grey Market Premium) is ₹40 as of June 15, 2026.

A GMP of ₹40 indicates positive sentiment among investors. However, Grey Market Premium changes daily and should not be considered the sole factor while making investment decisions.

Company Financial Performance

Financial Highlights (₹ Crore)

The company has delivered strong revenue growth and profitability over the last few years, supported by increasing demand for diagnostic products and medical equipment.

Cash Flow Analysis (₹ Lakh)

The negative investing cash flow reflects expansion and capital expenditure, which may support future growth.

Objectives of the Issue

The company plans to utilize the IPO proceeds for:

1. Setting Up a New Manufacturing Facility

• Investment of approximately ₹15.96 crore.

• Location: Medical Device Park, Sector-28, YEIDA, Gautam Buddha Nagar, Uttar Pradesh.

2. Working Capital Requirements

• Allocation of around ₹8.25 crore.

3. General Corporate Purposes

These initiatives are expected to strengthen manufacturing capacity and support future expansion.

Valuation and Key Ratios

The valuation appears reasonable considering the company's profitability and return ratios.

Strengths of Avience Biomedicals IPO

Diverse Product Portfolio

The company offers rapid test kits, analyzers, molecular diagnostic products, hematology devices, and medical equipment.

Strong Industry Experience

Management has significant expertise in biotechnology and diagnostics.

Expanding Distribution Network

Avience Biomedicals has established a strong domestic presence and is gradually expanding internationally.

Cost-Effective Solutions

Its affordable products help cater to a wider customer base.

Risks and Weaknesses

Dependence on Suppliers

Any disruption in raw material supply could affect operations.

High Research and Development Costs

Continuous innovation requires significant investments.

Intense Competition

The diagnostics and medical devices market is highly competitive.

Regulatory Risks

Compliance with medical regulations and approvals remains crucial for business growth.

Promoters and Management

The company is promoted by:

• Mr. Dharam Deo Choudhary

• Mr. Ram Nagina Choudhary

• Mr. Janardan Pal

• Ms. Deepa Choudhary

Shareholding Pattern

IPO Lot Size

Retail Investors

• Minimum Investment: 2 Lots

• Shares: 1,200 Shares

• Investment Amount: ₹2,49,600

HNI Investors

• Minimum: 3 Lots

• Shares: 1,800 Shares

• Investment Amount: ₹3,74,400

Dividend History

The company has not declared any dividends during the last three financial years, indicating that profits are being reinvested for growth and expansion.

Avience Biomedicalas IPO Review

Avience Biomedicals operates in the fast-growing biotechnology and diagnostics sector with a diversified product portfolio and improving financial performance. The company has posted healthy margins, strong return ratios, and reasonable valuations.

The current Avience Biomedicalas IPO GMP of ₹40 reflects positive market sentiment. However, investors should also consider factors such as competition, regulatory challenges, and dependence on suppliers before investing.

Long-term investors looking for exposure to the healthcare diagnostics segment may keep this IPO on their watchlist after evaluating their risk profile.

Conclusion

The Avience Biomedicalas IPO GMP and company fundamentals indicate a promising growth story in the medical diagnostics and biotechnology sector. With expansion plans, strong profitability, and a growing market presence, Avience Biomedicals appears well-positioned for future growth. Nevertheless, investors should conduct their own research and consult financial advisors before making investment decisions.

Disclaimer

This article is intended for educational and informational purposes only and should not be construed as investment advice. Investors are advised to read the RHP carefully and seek professional guidance before investing in the IPO.